Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Alembic (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and calcium‑channel pathways to lower blood pressure.

• Hypertension: provides combined blockade of angiotensin II receptors, calcium‑channel mediated vasoconstriction, and diuresis to achieve better blood‑pressure control.
• High‑risk cardiovascular patients: helps reach guideline‑recommended blood‑pressure targets when single‑agent therapy is insufficient.
• Resistant hypertension: adds complementary mechanisms to overcome inadequate response to monotherapy.

• The combination tablet contains three agents that act synergistically: olmesartan medoxil blocks AT1 receptors, preventing angiotensin II‑driven vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide reduces sodium and water reabsorption in the distal tubules, decreasing plasma volume. Together they produce additive reductions in systemic vascular resistance and circulating volume, resulting in lowered arterial pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially after the first dose.
• Fatigue: general feeling of tiredness.
• Increased urination: due to the diuretic component.
• Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects

• Hyperkalemia: elevated blood potassium levels.
• Acute kidney injury: sudden decline in renal function.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Angio‑edema: swelling of lips, tongue or airway.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Blood dyscrasias: rare blood‑cell abnormalities.

Before initiating therapy, clinicians should assess patient history and monitor laboratory parameters.

• Renal function: evaluate serum creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor potassium and sodium levels, especially with diuretic use.
• Hepatic disease: use cautiously in patients with liver impairment.
• Pregnancy: avoid use in pregnancy; teratogenic risk is associated with ARBs.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at below 25°C: keep tablets in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid)

• Aliskiren: combined renin‑angiotensin blockade can cause renal failure and hyperkalemia.
• Potassium‑sparing diuretics or supplements: increase risk of hyperkalemia.
• NSAIDs (high dose): may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase serum lithium levels, risking toxicity.
• CYP3A4 inhibitors (e.g., clarithromycin): can raise amlodipine concentrations.
• Antidiabetic agents: enhanced glucose‑lowering effect may require dose adjustment.